Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340119 · ClinicalTrials.gov registry record
Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 871
- Enrollment target
NCT00340119: Completed study, sponsored by National Cancer Institute (NCI).
NCT00340119 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 871 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00340119 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 871 participants
- Enrollment target
Study Summary
This study, done in collaboration with Johns Hopkins University School of Public Health in Baltimore, Maryland, will examine the role of genes in the development of atherosclerotic cardiovascular disease (CVD) in patients undergoing kidney dialysis. The rate of illness and death from CVD among patients on dialysis is extraordinarily high, accounting for about 50 percent of deaths. Blood levels of inflammatory markers are elevated in these patients, strongly predicting illness and death from CVD. The discovery of gene variants related to the inflammatory process in atherosclerotic CVD may lead to better medical treatments and improved survival in patients with end-stage kidney disease. Participants of John's Hopkins University's CHOICE (Choices for Healthy Outcomes in Caring for End-Stage Renal Disease) program are included in this study. Blood samples previously collected from these patients will be analyzed in the laboratory for genes that might be associated with the inflammatory process and atherogenesis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 871 participants |
| Start Date | 2005-03-21 |
| Est. Completion | 2012-03-01 |
What the finished NCT00340119 record still lists
NCT00340119 is an observational study that tracks outcomes without assigning an intervention. The registered 871 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00340119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00340119 about?
NCT00340119 is a clinical study titled "Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis". This study, done in collaboration with Johns Hopkins University School of Public Health in Baltimore, Maryland, will examine the role of genes in the development of atherosclerotic cardiovascular disease (CVD) in patients undergoing kidney dialysis. The rate of illness and death from CVD among patie...
What is the current status of trial NCT00340119?
This trial is currently completed. The enrollment target is 871 participants. The study started on 2005-03-21. Estimated completion is 2012-03-01.
Who is sponsoring clinical trial NCT00340119?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI